The GSK share price (LSE: GSK) leapt to 1,460p today. Here’s why!

The GSK share price briefly jumped above 1,460p on Tuesday morning, before cooling off in the afternoon. Here’s why the shares are up today.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

On Tuesday morning, GlaxoSmithKline (LSE: GSK) shares were limping along, opening down at 1,383p before rising to 1,390.2p at 10.50am. Then, the GSK share price suddenly took off, leaping by 70p (+4.7% on Monday’s close of 1395.2p) to hit an intra-day high of 1,460.20p. What caused the shares to suddenly jump before lunchtime? There are two possibilities.

GSK share price lifted by bid talk?

One reason for the GSK share price’s sudden rise was a story on Bloomberg business news. In this exclusive, published around 11am, the news site revealed that the UK pharma giant’s consumer healthcare division was being stalked by potential buyers. GSK plans to split itself into two distinct companies in 2022: consumer healthcare and biopharma. However, according to Bloomberg, private equity firms are “circling” the consumer healthcare arm as a potential takeover target. Other bidders might include other pharmaceutical and FMCG (fast-moving consumer goods) rivals. This may explain the GSK share price jumping earlier today.

In what it’s describing as potentially “the biggest buyout of all time“, Bloomberg reckons the consumer arm could be valued at over £40bn ($54bn). Potential suitors include the likes of Advent International, CVC Capital Partners, and KKR. Given the sheer scale of any sale, several buyout groups could team up to make a combined bid for part of the UK’s second-largest healthcare company. Bloomberg reports that the unit’s yearly sales exceeded £10bn in 2020. But CEO Dame Emma Walmsley has been planning to split GSK into two distinct businesses for nearly three years. As things stand, the group remains on track to lists its consumer healthcare unit in London in mid-2022, nine months away. By 2.15pm, the GSK share price had dropped back to trade at 1,429.4p, up 36.6p

Stock helped by vaccine news?

An alternative explanation for the GSK share price’s quick leap could be another news report, this time on Covid-19 vaccines. The Financial Times reported that CureVac has abandoned its first vaccine. Instead, the German biotech will focus on developing a more promising new jab with partner GSK. Despite being the world’s leading supplier of vaccines, GSK has fallen behind the curve in developing effective vaccinations against the coronavirus. The FT also reported that CureVac’s phase-three trials revealed a weak 48% efficacy rate overall. Hence, the group withdrew its application to the European Medicines Agency (EMA) for regulatory approval. The second vaccine “appears to elicit 10 times more antibodies [in animal trials] than the first vaccine“, according to the FT. The partners are also working on a joint coronavirus and influenza (flu) jab.

I still own this stock

On 18 August, the GSK share price hit a 52-week high of 1,528.8p. Today, the stock is roughly £1 below that level, valuing the firm at £71bn. I own GSK shares and have done for almost 30 years. Alas, I’m kicking myself for not selling when the shares peaked in late August. But if a bidding war does erupt for consumer healthcare, then it might send the shares soaring again. If the group can get a higher price by selling the division than it could hope to by listing it, then selling may be the better option. Also, a formal auction of the unit might flush out several firm bidders. Hence, for now, I will hang onto my GSK stock and await developments!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how long it’s taken £1k of Nvidia stock to turn into £10k today!

Our writer explains how money invested in Nvidia stock less than three years ago has grown in value over tenfold…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
US Stock

3 red flags I’m seeing right now for the S&P 500

Jon Smith points out some concerns he has with the S&P 500 at current levels and picks one stock he's…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

UK dividend shares are outperforming US tech stocks!

UK dividend shares aren’t just for passive income investors. Over the last 12 months, they’ve been outperforming their US tech…

Read more »

DIVIDEND YIELD text written on a notebook with chart
US Stock

Here’s how much passive income an investor could make with £2k in Meta stock

Jon Smith looks at Meta stock from a different angle to normal, considering it as an option for an investor's…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

1 of my top UK shares is up 15% in a day! Is it still a buy for me?

Celebrus shares are soaring after strong full-year results. At a P/E ratio below 13, is it one of the best…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

£10,000 invested in Jet2 shares 2 years ago is now worth…

Jet2 shares have surged in recent months and finally appear to be pushing towards fair value. Dr James Fox shares…

Read more »

piggy bank, searching with binoculars
Investing Articles

This FTSE 100 blue-chip could rise 26% in 12 months, according to brokers

While this FTSE 100 dividend stock has put investors through the wringer in recent years, some analysts see brighter skies…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

A 3-step passive income strategy to target major wealth

Want to invest in the stock market to build up a passive income stream? There's no fiendlishly complex multi-step mystique…

Read more »